Table 1 Descriptive characteristics of endometriotic patients with BARD1 expression

From: MiR-210-3p protects endometriotic cells from oxidative stress-induced cell cycle arrest by targeting BARD1

 

BARD1 negative

BARD1 positive

P a

Patients (n)

38

19

 

Age (years)

30.13 ± 3.45

29.95 ± 3.582

0.615

Height (m)

1.62 ± 0.05

1.59 ± 0.04

0.048

Weight (kg)

54.21 ± 9.11

52.29 ± 6.39

0.415

BMI (kg/m2)

20.58 ± 3.26

20.58 ± 2.59

0.999

Haemoglobin (g/dL)

11.52 ± 0.62

11.05 ± 0.21

0.333

Menstrual phage (%)

 Proliferative

33

16

1.000

 Luteal

5

3

 

EM Endometriosis stage

 I–II

25

19

0.030 b

 III–IV

13

0

 

Endometrial thickness

0.725 ± 0.20

0.75 ± 0.27

0.741

rAFS revised American Fertility Society Score

16.45 ± 15.52

4.26 ± + 2.23

0.001 b

Lesion size (cm)

7.45 ± 10.84

1.32 ± 1.67

0.021 b

Dysmenorrhoea pain scores

3.79 ± 3.00

2.89 ± 2.54

0.271

Chronic pelvic pain scores

6.47 ± 2.56

4.68 ± 2.14

0.014 b

AMH Anti-Mullerian Hormone (ng/mL)

2.97 ± 2.14

2.98 ± 2.72

0.889c

CA-125 Cancer Antigen 125 (U/mL)

81.10 ± 50.35

65.10 ± 30.74

1.000c

  1. BMI body mass index
  2. aData was compared by Student t-test or by rank test with Mann–Whitney U when accorded with normal distribution and homogeneity of variance, or analysed by chi square test when was categorical variables
  3. bValues in bold indicated significant correlation
  4. cOnly a part of the data was evaluable, due to no measurement of the hormones for some patients
Back to article page